

Resource Summary Report

Generated by [NIF](#) on Aug 1, 2026

Ki-67

RRID:AB_2738577

Type: Antibody

Proper Citation

BD Biosciences Cat# 564071, RRID:AB_2738577

Antibody Information

URL: http://antibodyregistry.org/AB_2738577

Proper Citation: BD Biosciences Cat# 564071, RRID:AB_2738577

Target Antigen: Ki-67

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Intracellular staining (flow cytometry)

Antibody Name: Ki-67

Description: This monoclonal targets Ki-67

Target Organism: rat, mouse, rhesus, human

Clone ID: B56

Antibody ID: AB_2738577

Vendor: BD Biosciences

Catalog Number: 564071

Record Creation Time: 20250819T233600+0000

Record Last Update: 20250820T055003+0000

Ratings and Alerts

No rating or validation information has been found for Ki-67.

No alerts have been found for Ki-67.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Galvez-Cancino F, et al. (2025) Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies. *Immunity*, 58(5), 1236.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. *Immunity*, 58(7), 1742.

Schimmer S, et al. (2025) Dietary lipid overload creates a suppressive environment that impedes the antiviral functions of NK cells. *iScience*, 28(5), 112396.

Mortazavi Farsani SS, et al. (2025) Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy. *Cell metabolism*, 37(6), 1294.

Humblin E, et al. (2025) The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells. *Immunity*, 58(8), 1966.

Lamorte S, et al. (2025) Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. *Cancer cell*, 43(5), 955.

Stockmann AP, et al. (2025) DF6215, an α -optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. *Cell reports. Medicine*, 102518.

Lanzar ZR, et al. (2025) De-coupling immune parameters and toxicity associated with IL-12 agonism. *Cell reports*, 44(6), 115840.

Lanzar ZR, et al. (2025) IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, 122(50), e2519141122.

Lacinski RA, et al. (2024) Nanosphere pharmacodynamics improves safety of immunostimulatory cytokine therapy. *iScience*, 27(2), 108836.

Guizar P, et al. (2024) An HIV-1 CRISPR-Cas9 membrane trafficking screen reveals a role for PICALM intersecting endolysosomes and immunity. *iScience*, 27(6), 110131.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. *Cell reports*, 43(5), 114141.

McCallion O, et al. (2024) Regulatory T cell therapy is associated with distinct immune regulatory lymphocytic infiltrates in kidney transplants. *Med (New York, N.Y.)*, 100561.

Wang K, et al. (2024) Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺ T cells. *Cancer cell*, 42(9), 1582.

Raeber ME, et al. (2024) Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. *Immunity*, 57(9), 2232.

Istomine R, et al. (2023) The eIF4EBP-eIF4E axis regulates CD4⁺ T cell differentiation through modulation of T cell activation and metabolism. *iScience*, 26(5), 106683.

Meednu N, et al. (2022) Dynamic spectrum of ectopic lymphoid B cell activation and hypermutation in the RA synovium characterized by NR4A nuclear receptor expression. *Cell reports*, 39(5), 110766.

Demaria O, et al. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. *Cell reports. Medicine*, 3(10), 100783.

Wieland A, et al. (2021) Defining HPV-specific B cell responses in patients with head and neck cancer. *Nature*, 597(7875), 274.

Rodda LB, et al. (2021) Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell*, 184(1), 169.